3,540 press releases in English indexed under healthcare.
ARLINGTON, Va., Sept. 10, 2026 -- During We Card Awareness Month this September, all retailers are encouraged to sharpen their employee training and reinforce compliance efforts as FDA enforcement of age-restricted product sales remains a critical focus. Now in its 31st year,...
The biotech space is ripe with attractive rebound setups. $NVS, $NTHI, $TNON, $IRD, $LLY, $AMGN, and $BIAF
NATICK, Mass., Sept. 10, 2026 -- Franklin Pierce University announced a partnership with Uwill, the leading mental health and wellness solution for colleges and students, to build upon the college's existing counseling options. Uwill's proprietary technology facilitates...
In the news release, SQAIRZ Launches SQAIRZ Medical, issued 10-Sep-2026 by SQAIRZ over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: SQAIRZ Launches SQAIRZ Medical New Division...
The appointment strengthens SHIFT's ability to bring evidence-based support to construction and industrial workers facing some of the country's toughest workforce-health challenges. Dr. Brandi Luedtke, PsyD, HSPP SHIFT has launched its Clinical & Performance Advisory Council to bring...
NEW YORK, Sept. 10, 2026 -- NYU Langone Health's Perlmutter Cancer Center has appointed Sean L. Berry, PhD, as vice chair of physics and dosimetry in the Department of Radiation Oncology. Dr. Berry brings more than 20 years of experience in radiation oncology physics, with...
Company announcement – No. 47 / 2026
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001 in new indications and combination regimens
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
New research builds on earlier findings showing HFSA's OMT-HF program improves clinician confidence in delivering guideline directed medical therapy WASHINGTON, Sept. 10, 2026 -- New research published in the Journal of Cardiac Failure provides additional evidence that...
Instinct Science announces Attending, a clinical AI assistant for veterinarians, powered by the industry's most trusted content.
SANTA ANA, Calif., Sept. 10, 2026 -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company’s lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.